tbuckley/cabot-search huggingface dataset:
Pathology and laboratory medicine
Authors: R. L. Reddick
Journal: JAMA (1995)

The field of pathology and laboratory medicine continues to advance in terms of instrumentation and automation to provide laboratory information for patient care as well as in the application of new scientific knowledge to patient care. We highlight selected examples from both types of advances. Automation began to be widely used in the larger centralized laboratories in the 1960s and 1970s. Since that time, essentially all of the high-volume analytical procedures have been successfully automated, including clinical chemistry, hematology counts and differential counts, and, more recently, coagulation and much of microbiology. The postanalytical reporting of the data has been automated by use of computer systems on-line to the analytical instruments. The one area of the laboratory that has resisted successful automation until recently is the "front end" or preanalytical area, ie, specimen handling, including centrifugation (when necessary) and removal of plasma or serum samples for the various tests. Thanks to
Evidence for 5-HT1D but not 5-HT1D receptor subtype expression in canine large coronary arteries and saphenous vein
Authors: F. Sgard, C. Faure, D. Graham
Journal: Cardiovascular Research (1996)

Objective5-Hydroxytryptamine1D (5-HT1D) receptors are believed to play a major role in the vasoconstriction of vascular smooth muscle in human coronary arteries. However, unequivocal evidence as to which subtype of this receptor (5-HT1Dα or 5-HT1Dβ) is involved in these vasoconstrictory effects is lacking. The aim of this study was to identify in the dog the 5-HT1D receptor subtype encoding mRNAs expressed in several large coronary arteries and in the saphenous vein.
A MULTIPLE SYSTEM DISEASE
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Firearm-related assaults on Los Angeles roadways
Authors: E. C. Onwuachi-Saunders
Journal: JAMA (1989)

During the summer of 1987, we investigated a series of firearm assaults occurring on Los Angeles County (California) roadways. Using law enforcement records, we identified 137 incidents of roadway assaults with firearms. Of these 137 incidents, 39% were brandishings and 61% were shootings. Of the shootings, 20% resulted in injuries; two were fatal. We compared the findings for June through August 1987 with findings for earlier years and found that the incidence rate of freeway firearm assault had increased each year from 1985 through 1987 for both freeway shootings and brandishings. We also found a positive association between freeway congestion and freeway firearm assaults in 1987. (<i>JAMA</i>. 1989;262:2262-2264)
Leads from the MMWR. Chloroquine-resistant Plasmodium falciparum malaria in West Africa
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract A18: Diagnostic and prognostic utility of urinary creatine riboside for early stage non-small cell lung cancer
Authors: Takahiro Oike, Yasuyuki Kanke, Amelia Parker, Majda Haznadar, Kristopher W. Krausz, Elise D. Bowman, Ana I. Robles, Frank J. Gonzalez, Curtis C. Harris
Journal: Clinical Cancer Research (2018)

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR02) of the Conference Proceedings. Citation Format: Takahiro Oike, Yasuyuki Kanke, Amelia Parker, Majda Haznadar, Kristopher W. Krausz, Elise D. Bowman, Ana I. Robles, Frank J. Gonzalez, Curtis C. Harris. Diagnostic and prognostic utility of urinary creatine riboside for early stage non-small cell lung cancer [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr A18.
Subject Index
Authors: Philip Snaith, Myriam van Moffaert, Fabio Facchinetti, Giovanni A. Fava, Koen Demyttenaere, Loredana Fioroni, Isabella Neri, Andrea R. Genazzani, Erwin K. Koranyi, Walter M. Potoczny, Barry Blackwell, Rachel Rothschild, Frederic M. Quitkin, Jambur Ananth, Karen Johnson, Gustavo Rodrigo, Mabel Lusiardo, Randall S. Jorgensen, George E. Schreer, Lara Baskin, Monica Kolodziej, Patricia L. Dobkin, Robert O. Pihl
Journal: Psychotherapy and Psychosomatics (1992)
Vanishing Pancreas
Authors: Stuart H. Danovitch
Journal: JAMA (1985)

THE "vanishing pancreas" is a sobriquet for lipomatous replacement of the gland and is occasionally a clinically evident phenomenon causing symptoms and malabsorption.<sup>1,2</sup>In children it is rare; it occurs with skeletal abnormalities and cytopenias and differs from cystic fibrosis in that sweat test results are normal.<sup>3,4</sup>In adults, the entity is recognized infrequently. Two cases were reported in 1959 from the Mayo Clinic, and their review revealed six other published cases in the literature.<sup>2</sup>Subsequently, scattered reports have appeared and the availability of computed tomography has increasingly led to the recognition of this entity prior to surgery or autopsy.<sup>4,5</sup>In the last six months we have seen two adults with long-standing digestive complaints, diabetes, and steatorrhea whose pancreata had vanished. <h3>Report of Cases</h3><h3>Case 1.—</h3> A 70-year-old woman has had chronic problems of obesity, mild hypertension, episodic diarrhea, and flatulence for ten to 15 years.
Can oral chemotherapy parity laws reduce patients’ out-of-pocket (OOP) costs?
Authors: Andrea Phillips Sitlinger, Rishi Sachdev, Peter A. Ubel, Charlene Wong, Thomas William LeBlanc, Tian Zhang, David Anderson, Yousuf Zafar
Journal: Journal of Clinical Oncology (2018)

6620 Background: Insurance plans vary coverage for infusional (IV) vs oral drugs, leading some to suggest that patients on oral drugs pay more OOP than those on IV drugs. 43 states have passed laws requiring insurers to cover oral drugs equivalently to IV drugs. Yet, there is little evidence that these “parity laws” are effective. Our aim was to estimate impact of parity laws on OOP expenses for oral vs IV drugs. Methods: We sought to determine how quickly patients on oral vs IV drugs reach their plan’s annual OOP maximum (max) as a surrogate for OOP expense. We used 2017 data from Healthcare.gov public use files to generate cost-sharing profiles for all 3,092 unique Marketplace plans. Chronic lymphocytic leukemia (CLL) and metastatic prostate cancer (mPC) were chosen as two representative malignancies since both have accepted, first-line, IV and oral treatment options. We created guideline-concordant, first-line treatment regimens for simulated patients with CLL (oral ibrutinib vs IV bendamustine/rituximab) or mPC (oral abiraterone vs IV docetaxel). Drug, professional, facility, imaging, and lab claims were simulated to calculate OOP costs. The mean number of days to reach the OOP maximum for each Marketplace plan and treatment regimen were recorded. We assessed variation according to insurance coverage levels (“metal tier”: Catastrophic, Bronze, Silver, Gold, Platinum). Results: For CLL patients, 95% of plans reached OOP max in approximately one month of treatment for both oral and IV drugs (oral: mean 36 days; IV: mean 29 days). 99% of mPC patients reached their OOP max for oral treatment in a mean 15 days, but only 57% of plans reached OOP max for IV mPC treatment. Metal tier impacts time to reach OOP max (table). Conclusions: Parity laws do not lower patient costs when both IV and oral treatment options are expensive. In these cases, patients reach the OOP max rapidly. The small subset of patients most likely to benefit from parity laws are those on oral therapy for a disease where the comparable IV drug is inexpensive (eg, generic docetaxel for mPC). Metal tier Days to Reach OOP Maximum CLL mPC IV Oral IV Oral Catastrophic 1 1 190 1 Bronze 2 8 211 1 Silver 28 36 327 29 Gold 29 36 327 29 Platinum 113 36 285 29
Tumor markers aid therapy of testicular cancer
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
N.H.S. Contraceptive Services
Authors: G. Pickering, C. Deys, D. V. I. Fairweather, C. M. Fletcher, P. J. Huntingford, J. P. Lester, G. Morris, J. A. Loraine, D. E. Robertson, M. Smith, T. Stuttaford, None Taylor, B. Tonge, D. P. Winstanley
Journal: BMJ (1974)
The Cover
Authors: —M. Therese Southgate
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Retransplantation of Scarce Organs: The Ethical Lessons
Authors: Richard McMasters
Journal: JAMA (1994)

<h3>To the Editor.</h3> —In a recent article, Dr Ubel and colleagues<sup>1</sup>argue that candidates for liver retransplant should receive a lower priority than candidates for primary transplant because of reduced 1-year survival. Looking at data in the aggregate may obscure important heterogeneities in retransplant candidates. For instance, Mora et al<sup>2</sup>divided retransplant candidates into two groups—nonelective and elective. They found that there was no statistically significant difference in actuarial survival between patients who received elective retransplants and primary transplants; however, both groups did much better than the nonelective retransplant group. Elective retransplants were usually performed because of chronic rejection or hepatic artery thrombosis, whereas nonelective transplants often followed primary graft failure or acute rejection. Another possible heterogeneity applies to age group. For instance, although the data of Saito et al<sup>3</sup>show a survival difference between first and second transplants, the difference is much less pronounced in children
Downregulation of c-kit (Stem Cell Factor Receptor) in Transformed Hematopoietic Precursor Cells by Stroma Cells
Authors: Christoph Heberlein, Jutta Friel, Christine Laker, Dorothee von Laer, Ulla Bergholz, Martina Bögel, Leonie K. Ashman, Karl Klingler, Wolfram Ostertag
Journal: Blood (1999)
School dinners.
Authors: B A Wharton
Journal: BMJ (1987)

Asymptomatic carotid stenosis: spare the knife We regret that an error occurred in the numbering of the references in this leading article by Peter Sandercock (30 May, p 1368).In the fourth paragraph the reference number after the sentence "The annual risk of ipsilateral ischaemic thromboembolic stroke may be as low as 0-1% per year" should have been 4, not3~.
Cuestiones Gastroenterológicas.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Air Pollution and Daily Hospital Admissions in Metropolitan Los Angeles
Authors: William S. Linn, Yaga Szlachcic, Henry Gong, Patrick L. Kinney, Kiros T. Berhane
Journal: Environmental Health Perspectives (2000)

We used daily time-series analysis to evaluate associations between ambient carbon monoxide, nitrogen dioxide, particulate matter [less than and equal to] 10 microm in aerodynamic diameter (PM(10)), or ozone concentrations, and hospital admissions for cardiopulmonary illnesses in metropolitan Los Angeles during 1992-1995. We performed Poisson regressions for the entire patient population and for subgroups defined by season, region, or personal characteristics, allowing for effects of temporal variation, weather, and autocorrelation. CO showed the most consistently significant (p<0.05) relationships to cardiovascular admissions. A wintertime 25th-75th percentile increase in CO (1.1-2.2 ppm) predicted an increase of 4% in cardiovascular admissions. NO(2), and, to a lesser extent, PM(10) tracked CO and showed similar associations with cardiovascular disease, but O(3) was negatively or nonsignificantly associated. No significant demographic differences were found, although increased cardiovascular effects were suggested in diabetics, in whites and blacks (relative to Hispanics and Asians), and in persons older than 65 years of age. Pulmonary disease admissions associated more with NO(2) and PM(10) than with CO. Pulmonary effects were generally smaller than cardiovascular effects and were more sensitive to the choice of model. We conclude that in Los Angeles, atmospheric stagnation with high primary (CO/NO(2)/PM(10)) pollution, most common in autumn/winter, increases the risk of hospitalization for cardiopulmonary illness. Summer photochemical pollution (high O(3)) apparently presents less risk.
Cost and effectiveness of genetic testing in metastatic colorectal cancer (mCRC) at Montefiore Medical Center (MMC).
Authors: Nadia Ashai, Matthew Stuart, Mateo Mejia Saldarriaga, Wei Zhang, Renee Huang, Rahul Narang, Jennifer W. Chuy, Andreas Kaubisch, Sanjay Goel, Balazs Halmos, Lakshmi Rajdev
Journal: Journal of Clinical Oncology (2019)

e15043 Background: Upfront testing for MSI, and mutations in KRAS, NRAS, and BRAF is recommended. The most cost-effective way of obtaining this information remains unclear. We examined cost of broad next generation sequencing (NGS), in comparison to hotspot (HT) and individual target (IT) testing in patients with mCRC with Medicare (MC) and commercial insurance (CI) at MMC. As a surrogate of effectiveness, we hypothesize that patients with NGS are more likely to enroll in clinical trials. Methods: Cost of individual and hotspot tests were derived from known reimbursement rates with insurances affiliated with MMC. Due to ongoing changes in current procedural terminology for NGS, we used known reimbursement amounts from our patients. We applied these costs to a model population of 1,000,000 people. We then evaluated clinical trial enrollment of patients who had either NGS or hotspot/individual testing. Results: MC costs for IT, HT, NGS testing were $1,504, $752, and $4,680 respectively. CI costs were $1,910, $814, $2,366 for IT, HT, and NGS testing respectively. When applied to our model population, NGS cost $914,604 and $1,131,016 more than individual and hot spot testing respectively for MC patients, and $21,432 and $72,924 more for CI patients. Analysis of effectiveness included 136 patients, wherein 8% of those with NGS (n = 5/61) were enrolled in clinical trials as a result of testing compared to 1% of those with HT/IT (n = 1/75). Conclusions: Broad spectrum NGS costs more than individual or hot spot testing in mCRC. However, patients with NGS testing were more likely to be enrolled in clinical trials, suggesting the need for studies to further evaluate ideal testing modality. [Table: see text]
THE SURGICAL ASPECTS OF MAJOR NEURALGIA OF THE TRIGEMINAL NERVE.A REPORT OF TWENTY CASES OF OPERATION ON THE GASSERIAN GANGLION, WITH ANATOMIC AND PHYSIOLOGIC NOTES ON THE CONSEQUENCES OF ITS REMOVAL
Authors: HARVEY CUSHING
Journal: JAMA (1905)

<h3>Liberation and Extraction of the Ganglion and Its Branches.</h3> We now come to the method of dealing with the ganglion, and here, no matter what the approach has been, difficulties in a certain percentage of cases are invariably encountered. Hemorrhage is the chief bugbear, and I confess to have dwelt too lightly on it in my earlier paper. My first two cases were fortunately, or unfortunately, unusually bloodless ones. Not uncommonly, I think in more than one-half of my cases, has it. been possible, with almost no loss of blood, to arrive at this stage of the operation. Sometimes it may be completed and the ganglion removed without any difficulties whatever arising from bleeding, and this has been my good fortune on six occasions, but at other times the structure is "below water" much of the time.<sup>23</sup> There are certain advantages, I think, which come from working in a small hole and under the artery, provided that there is a good overhead light, for with the manipulations necessary
Fulminant hepatic failure caused by ecarazine hydrochloride (a hydralazine derivative)
Authors: Y TAMEDA
Journal: Hepatology (1996)

The cause of fulminant hepatic failure is reported to be unknown in more than half the cases in Japan. We recently reviewed 23 cases of fulminant hepatic failure that had been treated at our hospital. The cause of disease had been regarded as unknown before this study. It was found that seven of these patients had been under ecarazine hydrochloride therapy when they developed fulminant hepatic failure. We examined the reasons why fulminant hepatic failure in these seven patients had not been previously attributed to ecarazine, and found that it could be explained by the following factors: (1) the time from the start of ecarazine therapy to the onset of hepatic failure was long; (2) in all cases, hepatic failure developed more than 10 days after the clinical recognition of hepatitis; and (3) characteristic signs of drug-induced hepatic failure such as a skin rash and positive lymphocytes stimulation test with the drug were absent in all cases. Fulminant hepatic failure in these cases could be characterized by: (1) rapid decrease in serum alanine transaminase (ALT) level after discontinuation of ecarazine, (2) prolonged jaundice despite discontinuation of ecarazine, (3) high incidence of anti-nuclear antibody (ANA) (57%), and (4) histological findings of extensive hepatocellular necrosis ranging from bridging necrosis to massive necrosis. Of the seven patients, four died of fulminant hepatic failure. These four patients had received high doses of ecarazine hydrochloride for prolonged periods. Our data suggest that there may be many cases in which the cause of fulminant hepatic failure or acute hepatitis was not previously determined that can be attributed to long- term drug therapy for chronic diseases.